CA-PLUS
9.5.2022 14:02:08 CEST | Business Wire | Press release
Plus, a global provider of self-driving truck technology, announced today that it has selected Velociti, a global leader in fleet technology solutions, as the deployment and maintenance partner for the national Plus Build program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510005059/en/
The Plus Build program takes less than a day to turn new and existing Class 8 freight trucks into semi-autonomous trucks by equipping them with state-of-the-art lidar, radar, and camera sensors and Plus’s proprietary autonomous driving software. The result is PlusDrive, the industry’s first commercially available autonomous trucking solution. PlusDrive improves safety, enhances driver comfort, and saves at least 10% in fuel costs. Installation is performed at locations most convenient to customers, in or near major transportation hubs across the U.S. Maintenance services are available nationwide by utilizing mobile resources to meet customers where they are.
Shawn Kerrigan, COO and Co-founder of Plus, said: “Plus Build helps companies unlock the benefits of autonomous driving technology today by quickly modernizing trucks to improve their safety and uptime. Velociti’s unmatched technology installation and service network will help us get PlusDrive into the hands of more truck drivers across the country to make their jobs safer, easier, and better.”
Through the Plus Build program and partnership with Velociti, Plus is now deploying PlusDrive nationwide. Some of the world’s largest fleets and truck manufacturers are already participating in Plus Build and are operating PlusDrive-enabled trucks on the road today. In addition to Velociti’s technology installation services, Plus is implementing Velociti’s VeloCare solution, a flagship proactive system-health monitoring program including remote and mobile services to maximize technology uptime.
“Partnering with Plus to provide our services as an important part of the PlusDrive solution leverages Velociti’s decades of experience deploying and maintaining innovative fleet technologies. We are excited to enter into this strategic partnership to help PlusDrive customers realize the benefits this transformational technology brings to their businesses and to the transportation industry,” said Ryan Powell, Senior Vice President at Velociti.
Supervised by a truck operator, PlusDrive can autonomously handle the following in normal traffic conditions on a highway:
- Lane centering
- Driver initiated lane change
- Traffic jam assist
- Predictive fuel optimization
- Adaptive cruise control (down to zero)
- Lane merging
- Driver attentiveness detection
- Operational Design Domain (ODD) checker
- Self-calibration
- Over-the-air updates
For more information on the Plus Build program or PlusDrive, please contact sales@plus.ai .
About Plus
Plus is a global leader in the autonomous trucking revolution, with award-winning high-performance full-stack driverless technology. Named by Fast Company as one of the World’s Most Innovative Companies of 2022, Plus is the only autonomous driving company with customers operating its product on the road today. Working with one of the largest companies in the U.S., vehicle manufacturers and others, Plus is making long-haul trucking safer, more fuel efficient, more sustainable, and more comfortable for the drivers. Plus has received a number of industry awards and distinctions for its transformative technology and business momentum from Fast Company , Insider , Consumer Electronics Show , AUVSI , and others.
For more information, please visit www.plus.ai or follow us on LinkedIn or YouTube .
About Velociti
Velociti, a global provider of enterprise technology solutions for more than 25 years, helps meet complex business needs by optimizing technology investments, lowering costs, and improving employee and customer experience. Its innovative design, rapid installation and deployment, and proactive support services for a broad range of transportation and networking technologies are provided by a highly experienced team of engineers, project managers, certified technicians and customer success representatives. Velociti serves enterprises in transportation and logistics, construction, retail, food service, manufacturing, distribution, government, and hospitality including many Fortune 500 companies.
For more information visit http://www.velociti.com or call toll free (855)-233-7210.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005059/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press release
Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom